Lv6
2030 积分 2021-12-10 加入
Efficacy and safety exposure–response analyses of entrectinib in patients with advanced or metastatic solid tumors
1个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
1个月前
已完结
Pharmacological targeting of oncogenic condensates in cancer: mechanistic insights and therapeutic opportunities
3个月前
已完结
[Development of a detection system (APC yeast color assay) of APC mutations by color change of yeast]
3个月前
已关闭
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
5个月前
已完结
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
5个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
6个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
6个月前
已完结
Response and Resistance to RAS Inhibition in Cancer
6个月前
已完结
Deep whole-genome analysis of 494 hepatocellular carcinomas
8个月前
已完结
皖公网安备34019202002308
